Trials / Completed
CompletedNCT02182518
Epinastine + Pseudoephedrine SR (Slow Release) Versus Epinastine Alone in Patients With Perennial Allergic Rhinitis
Double-blind, Randomized, Parallel Trial to Evaluate the Clinical Efficacy and Safety of Epinastine 10 mg + Pseudoephedrine 120 mg SR, Twice a Day, Versus Epinastine 10 mg Alone, Twice a Day, in the Treatment of Outpatients With Perennial Allergic Rhinitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 101 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this trial is to evaluate the clinical efficacy and safety of Epinastine 10 mg + Pseudoephedrine 120 mg slow release (SR) administered twice a day, compared to Epinastine 10 mg alone administered twice daily.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Epinastine | |
| DRUG | Pseudoephedrine | |
| DRUG | Placebo | Placebo during run-in period |
Timeline
- Start date
- 2000-05-01
- Primary completion
- 2001-07-01
- First posted
- 2014-07-08
- Last updated
- 2014-07-14
Source: ClinicalTrials.gov record NCT02182518. Inclusion in this directory is not an endorsement.